“With this provision, policymakers are rewriting the rules to benefit pharmaceutical manufacturers for slightly tweaking their product and reintroducing it as a new ‘innovation,’” CSRxP Executive Director John Rother said.
Join the Campaign for Sustainable Rx Pricing on Capitol Hill for a discussion about market-based policy solutions to curb rising drug prices.
“Abusing rules and regulations to keep competitors out of the market is common in the prescription drug industry, but AstraZeneca’s latest undertaking is especially egregious.”
“When the sticker price for 30 out of 39 of the most sold drugs goes up by more than double the rate of inflation, consumers are left holding the bag. These price increases year after year compound the problem and the whole scheme is unsustainable.”
“Prescription drug costs are rising much faster than other parts of Medicare and putting ever greater financial pressure on the program and on its beneficiaries. It’s no wonder that voters are making prescription drug prices a top issue in this election.”
The Campaign for Sustainable Rx Pricing (CSRxP) announced its endorsement of the Creating and Restoring Equal Access to Equivalent Samples (“CREATES”) Act, a bill introduced today in the Unites States Senate.
“This MEDPAC report confirms exactly what we have been saying: rising drug prices are putting a colossal burden on America’s health care system and now total nearly 20 percent of health care spending. Without market-based solutions like transparency, competition, and value, we can only expect the problem to get worse.”
“The pharmaceutical industry’s habit of hiking prices on life-saving medications is appalling. Our campaign has been active in drawing attention to the price spikes on naloxone and we welcome this bipartisan effort to expose pharma’s price gouging tactics.”
The American Gastroenterological Association announced today that it has joined the Campaign for Sustainable Rx Pricing, a broad-based campaign working to curb rising drug costs. AGA, which has 16,000 members involved in all aspects of gastroenterology around the globe, adds its voice to the hospitals, physicians, pharmacists, nurses, health plans, patients, and employers already promoting CSRxP’s solutions of transparency, competition, and value in the prescription drug market.
We need to move toward market-based solutions to increase transparency, promote competition, and enhance value. For the millions of Americans living with chronic conditions – including allergies and arthritis, these solutions cannot come soon enough.